Loading organizations...
Clock Bio is a biotechnology company based in Cambridge, United Kingdom, that develops regenerative medicines using human induced pluripotent stem cells to prevent and treat age-related diseases. The organization decodes rejuvenation biology across the human genome by utilizing an aging model that triggers cellular self-rejuvenation mechanisms. This scientific approach allows the company to build a comprehensive atlas of disease and rejuvenation targets intended for clinical translation. Operating with $4 million in initial funding backed by lead investor BlueYard Capital, the firm recently launched out of stealth mode after reaching its proof-of-concept milestone. The enterprise aims to extend human healthspan by two decades and plans to demonstrate these therapeutic outcomes in a Phase 3 clinical trial by the end of the decade. Clock Bio was incorporated in 2020 and was established by founder Mark Kotter.
Clock Bio has raised $9.0M across 2 funding rounds.
Clock Bio has raised $9.0M in total across 2 funding rounds.
Clock Bio has raised $9.0M in total across 2 funding rounds.
Clock Bio's investors include LocalGlobe, Jason Pontin, Magnetic Ventures.
Clock Bio has raised $9.0M across 2 funding rounds. Most recently, it raised $5.0M Seed in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2024 | $5M Seed | LocalGlobe | Jason Pontin, Magnetic Ventures | Announced |
| Aug 31, 2023 | $4M Venture Round | — | — | Announced |
clock.bio is a Cambridge-based biotech company pioneering rejuvenation biology to extend human healthspan by developing regenerative therapies that reverse cellular aging. It builds a high-throughput discovery platform decoding the "rejuvenation genome"—over 150 genes enabling cells to reverse aging—using proprietary technologies like the geneAge Atlas (CRISPR-based mapping), imAge (AI-driven single-cell age measurement), and clinAge (rapid clinical validation).[1][2][3][4] The company serves consumers and patients seeking anti-aging solutions, initially targeting skin rejuvenation topicals and nutraceuticals to quickly generate human data on biological age reversal, with ambitions for systemic therapies to extend healthspan by 20 years via Phase 3 trials by decade's end.[1][2][3] Backed by $5.3M in seed funding from LocalGlobe, BlueYard Capital, Onsight Ventures, and Jonathan Milner, clock.bio demonstrates strong early momentum post-stealth launch, with proof-of-concept in human iPSCs and key hires like CEO Markus Gstoettner and CTO Rodrigo Santos.[2][3][4]
Founded by Mark Kotter, a stem cell biologist and neurosurgeon at the University of Cambridge, clock.bio emerged from his vision to harness human pluripotent stem cells' natural rejuvenation ability, inspired by embryonic stem cells' regenerative potential.[2][3][4] Kotter, now Executive Chairman, developed a proprietary "aging in a dish" model using human induced pluripotent stem cells (hiPSCs) force-aged to mimic aging hallmarks, triggering self-rejuvenation and revealing genetic drivers via unbiased CRISPR screens.[2][3][4] The company launched out of stealth in 2024 with $4M initial funding, reaching proof-of-concept and raising a $5.3M seed round shortly after.[2][4] Pivotal early traction includes mapping the first genome-wide rejuvenation atlas with over 150 targets, validated in iPSCs, and strategic hires: Gstoettner (ex-Meatable co-founder with iPSC expertise) as CEO for commercialization, and Santos (iPSC programming expert) as CTO.[3][4] Based at the Milner Therapeutics Institute, this academic-industry nexus fueled rapid progress from idea to platform build.[3][4]
clock.bio stands out in longevity biotech through its integrated, translation-focused platform reversing aging rather than slowing it:
clock.bio rides the longevity biotech boom, targeting the $100B+ anti-aging market amid rising demand for healthspan extension as global populations age.[1][2] Its timing aligns with advances in AI, CRISPR, and iPSCs, enabling scalable decoding of complex aging biology previously intractable.[1][3][4] Market forces like biomarker-validated trials, regulatory interest in rejuvenation (e.g., FDA's aging focus), and investor enthusiasm for "aging in a dish" models favor it, positioning clock.bio to influence the ecosystem by open-sourcing rejuvenation insights and partnering for therapies.[2][3] By validating in human data rapidly, it accelerates the shift from senescence-targeting drugs to full cellular reset, potentially redefining preventive medicine and inspiring competitors in regen med.[1][4]
clock.bio is primed for global scale with its validated platform, recent leadership hires, and partnership push for topicals/nutraceuticals, setting up human proof-of-concept data soon.[3] Next steps include prioritizing druggable targets from its atlas, clinAge trials, and systemic therapy pipelines, fueled by additional funding rounds.[3][4] Trends like AI-biology convergence, iPSC scalability, and healthspan economics will propel it, potentially evolving its influence from pioneer to category leader in rejuvenation—delivering the 20-year healthspan extension that hooked investors from day one.[2]
